Cardiovascular implications of insulin resistance and non-insulin-dependent diabetes mellitus

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 15, Issue 6, 2001, Pages 768-777

  McNulty, Patrick H ^a   Ettinger, Steven M ^a   Gilchrist, Ian C ^a   Kozak, Mark ^a   Chambers, Charles E ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular complications; Diabetes mellitus; Insulin resistance

Indexed keywords

ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 0035676632     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcan.2001.28338     Document Type: Article

References (128)

1. Science, medicine and the future: Non-insulin-dependent diabetes mellitus: The gathering storm
2. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr
3. Pathophysiology and pharmacologic treatment of insulin resistance
4. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study
5. Predictors of morbidity and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registry
6. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia
7. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
8. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: An epidemic in progress
9. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is...or is it?
10. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-1 experience
11. Mortality from coronary heart disease in subjects with type-2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
12. Impact of diabetes on mortality after first myocardial infarction
13. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus
14. Clinical characteristics and long-term outcome in patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: Development of a predictive model
15. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans
16. Glucose clamp technique: A method for quantifying insulin secretion and resistance
17. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients
18. Impaired glucose tolerance as a disorder of insulin action: Longitudinal and cross-sectional studies of Pima Indians
19. The clinical implications of insulin resistance
20. The triumvirate: Beta-cell, muscle, liver: A collusion responsible for NIDDM
21. The glucose-fatty acid cycle: Its role in insulin sensitivity and the metabolic determinants of diabetes mellitus
22. Pathogenesis of NIDDM: A balanced overview
23. Cellular mechanisms of insulin resistance
24. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy
25. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate: Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus
26. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes
27. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus
28. The effect of insulin on the disposal of intravenous glucose: Results from indirect calorimetry and hepatic and femoral venous catheterization
29. Metabolic fate of extracted glucose in normal human myocardium
30. Metabolic and hemodynamic effects of insulin on human hearts
31. Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin-dependent diabetes mellitus
32. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy
33. NMR studies of muscle glycogen synthesis in insulin-resistant offspring of parents with non-insulin-dependent diabetes mellitus immediately after glycogen-depleting exercise
34. The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle
35. The hormonal control of glycogen metabolism in mammalian muscle by multisite phosphorylation
36. Signaling mechanisms that regulate glucose transport
37. Signalling pathways in insulin action: Molecular targets of insulin resistance
38. Expression of a constitutively active Akt ser/thre kinase in 3T3-L 1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation
39. Roles for insulin receptor, PI3-kinase and Akt in insulin-signalling pathways related to production of nitric oxide in human vascular endothelial cells
40. Mechanisms of disease: Regulatory functions of the vascular endothelium
41. Vascular dysfunction in diabetes mellitus
42. Endothelial function, insulin sensitivity, and hypertension
43. Induction of endothelin-1 expression by glucose: An effect of protein kinase C activation
44. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
45. Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques
46. Insulin-mediated skeletal muscle vasodilatation contributes to both insulin sensitivity and responsiveness in lean humans
47. Insulin-mediated skeletal muscle vasodilatation is nitric oxide dependent: A novel action of insulin to increase nitric oxide release
48. Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance
49. Effect of plasma insulin level on myocardial blood flow and its mechanism of action
50. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: A novel mechanism for insulin resistance
51. Obesity/insulin resistance is associated with endothelial dysfunction
52. Insulin-mediated vasodilatation: Impairment with increased blood pressure and body mass
53. The coupling of glucose metabolism and perfusion in human skeletal muscle
54. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM
55. The vascular effects of L-arginine in humans: The role of endogenous insulin
56. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation
57. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production
58. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism
59. Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus
60. Endothelial response to cardiopulmonary bypass surgery
61. Microvascular responses to cardiopulmonary bypass
62. Circulating adhesion molecules in humans: Role of hyperglycemia and hyperinsulinemia
63. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells
64. Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
65. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
66. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells
67. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: A serial intravascular ultrasound study
68. Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients
69. The role of endothelium in thrombosis and hemostasis
70. Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry
71. Utilization of energy providing substrates in the isolated working rat heart
72. Glucose for the heart
73. Substrate metabolism as a determinant of postischemic functional recovery of the heart
74. Comparative 13C and 31P NMR assessment of altered metabolism during graded reductions in coronary flow in intact rat hearts
75. Ischemic preconditioning stimulates anaerobic glycolysis in the isolated rabbit heart
76. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion
77. Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia
78. The functional recovery of post-ischemic myocardium requires glycolysis during early reperfusion
79. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions
80. 2+ transport
81. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart
82. Enhanced utilization of exogenous glucose improves cardiac function in hypoxic rabbit ventricle without increasing total glycolytic flux
83. Protective effect of increased myocardial glycogen stores in cardiac anoxia in the rat
84. Insulin improves functional and metabolic recovery of reperfused rat heart
85. Determinants of a protective effect of glucose and insulin on the ischemic myocardium: Effects on contractile function, diastolic compliance, metabolism and ultrastructure during ischemia and reperfusion
86. Effects of ischemia and reperfusion on pyruvate dehydrogenase activity in isolated rat hearts
87. Pyruvate dehydrogenase influences postischemic heart function
88. Dichloroacetate stimulation of glucose oxidation improves recovery of perfused working rat heart
89. Dichloroacetate enhances myocardial functional and metabolic recovery following global ischemia
90. Ranolazine stimulates glucose oxidation in normoxic, ischemic and reperfused ischemic rat hearts
91. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem
92. The protective action of pyruvate on recovery of ischemic rat heart, comparison with other oxidizable substrates
93. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes
94. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo
95. Cardiac selective GLUT4 ablation exacerbates ATP depletion and contractile dysfunction during low-flow ischemia
96. Role of insulin resistance in human disease (syndrome X): An expanded definition
97. Insulin resistance characterizes glucose uptake in skeletal muscle but not the heart in NIDDM
98. Heart and skeletal muscle glucose disposal in type 2 diabetes as determined by positron emission tomography
99. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction
100. Outcome of unstable angina in patients with diabetes mellitus
101. One-year outcomes of diabetic versus non-diabetic patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty
102. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents
103. Mortality and morbidity during a five year follow-up of diabetics with myocardial infarction
104. Mild fasting glucose elevation increases the risk of death in non-diabetic patients undergoing percutaneous coronary intervention
105. Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: Relationship to infarct extent and mortality
106. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of free fatty acids during aerobic reperfusion of ischemic hearts
107. Energy metabolism of the heart: From basic concepts to clinical applications
108. Control of energy production in myocardial ischemia
109. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
110. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized, prospective 6-year study
111. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group
112. VII. Evaluation of insulin therapy: Final report
113. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
114. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials
115. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at one year
116. Metabolic modulation of acute myocardial infarction: The ECLA glucose-insulin-potassium pilot trial
117. Regulation of myocardial [13C]glucose metabolism in conscious rats
118. Emory Angioplasty versus Surgery Trial (EAST) investigators: Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST)
119. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation)
120. Clinical trials of revascularization therapy in diabetics
121. Influence of diabetes and mammary artery grafting on survival after coronary bypass
122. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty
123. Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations
124. Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting
125. Improved cardiac function with glucose-insulin-potassium after aortocoronary bypass grafting
126. Efficacy of metabolic support with glucose-insulin-potassium for left ventricular pump failure after aortocoronary bypass surgery
127. Glyburide, a KATP channel antagonist, attenuates the cardioprotective effect of isoflurane in stunned myocardium